The results showed that the sensitivity of cells to cetuximab increased with the increase of CHI3L1 in the concentration range of 31.25‐250 ng/mL, indicating that high level of CHI3L1 will increase the sensitivity of colon cancer cells to cetuximab (Figure 3C). This evidence concerns the gene CHI3L1 and malignant colon neoplasm.